CanSino Biologics Inc. (CASBF)
| Previous Close | 2.1000 |
| Open | 2.1000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.1000 - 2.1000 |
| 52 Week Range | 1.8600 - 4.8000 |
| Volume | |
| Avg. Volume | 416 |
| Market Cap | 1.064B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 13, 2022 |
| 1y Target Est | N/A |
- Reuters
China's CanSino seeks more vaccine contracts after AstraZenca deal
China's CanSino Biologics , which recently announced a contract manufacturing deal to support AstraZenca's messenger RNA (mRNA) technology vaccine programme, is in talks with more firms on similar deals, its CEO said, as it seeks new revenue streams to make up for plummeting COVID vaccine demand. CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino's CEO and co-founder Xuefeng Yu told Reuters in an interview. "This is the first step," he said, describing the AstraZenca deal announced earlier this month as "a business model".
- Reuters
UPDATE 1-China's CanSino in mRNA vaccine deal with AstraZeneca
CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday. In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca.
- Reuters
China's CanSino in mRNA vaccine deal with AstraZeneca
CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday. In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca did not have an immediate comment on the announcement.
